🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Adobe, Fox and Smith & Wesson Rise Premarket

Published 06/18/2021, 08:12 AM
Updated 06/18/2021, 08:13 AM
© Reuters.
GS
-
ADBE
-
BIIB
-
LEN
-
DAL
-
CDXS
-
SWBI
-
ALK
-
FOX
-
ATHA
-
ORPHY
-

By Peter Nurse 

Investing.com -- Stocks in focus in premarket trade on Friday, June 18th. Please refresh for updates.

  • Adobe (NASDAQ:ADBE) stock rose 2.8% after the software giant easily beat second-quarter targets, benefiting from customers moving towards a digital lifestyle by offering more mobile-based applications.

  • Fox Corp (NASDAQ:FOX) stock rose 1% after the entertainment announced plans to add $2 billion to its stock repurchase plan, bringing the total amount authorised to $4 billion.

  • Smith & Wesson (NASDAQ:SWBI) stock rose 4.5% after the gun manufacturer reported  strong quarterly results, a new share buyback program and a higher dividend. 

  • Lennar (NYSE:LEN) stock rose 1.4% after Goldman Sachs (NYSE:GS) upgraded its recommendation on the real estate company to ‘overweight’ from ‘neutral’, seeing nearly 50% upside in a hot housing market.

  • Athira Pharma (NASDAQ:ATHA) stock slumped 39% after the company placed its Chief Executive Officer Leen Kawas on temporary leave as it completes a review “stemming from doctoral research Dr. Kawas conducted while at Washington State University.”

  • Delta Air Lines (NYSE:DAL) stock rose 0.2% and Alaska Air (NYSE:ALK) stock rose 0.2% after Wolfe Research upgraded both airlines to ‘outperform’ from ‘underperform’ and ‘peer perform’ respectively, stating that the companies managed through the pandemic without needing to raise significant amounts of cash

  • Codexis (NASDAQ:CDXS) stock rose 3.1% after the enzyme engineering company announced a $13.9 million order from a global pharmaceutical company, lifting its guidance for FY 2021.

  • Orphazyme (NASDAQ:ORPH) stock slumped over 50% after the Food and Drug Administration rejected its experimental treatment for a rare genetic disorder known.

  • Biogen (NASDAQ:BIIB) stock rose 1.6% after Piper Sandler upgraded its investment stance to ‘overweight’ from ‘neutral’, citing the likely success of its newly approved Alzheimer’s drug Aduhelm.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.